HEALTH● LOWJul 22 · Jul 22, 2026, 9:27 PM
Pfizer gains priority review for Talzenna/Xtandi combo in prostate cancer
Seeking Alpha Tech
Pfizer has received priority review for its combination drug, Talzenna/Xtandi, for treating prostate cancer. This development could accelerate the availability of a new therapeutic option for patients.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH15m agoAfter patient’s evacuation, is Nigeria Ebola-free? WHO clarifiesVanguard NigeriaHEALTH44m ago‘Hybrid weapon of war’: Why climate disinformation could be a growing public health threatEuroNews [en]HEALTH1h agoLaunch of virtual autopsy at Kozhikode Medical College Hospital likely to take timeThe HinduHEALTH1h agoDuchess Hospital marks five years of giant milestonesPremium Times